Expertise in
27
conditions

Dr. Mark J. Fesler

Hematology Oncology | Transplant Surgery | Hematology
Van Amburg And Busiek Mds LLC
232 S Woods Mill Rd, Suite 330e, 
Chesterfield, MO 
Accepting New Patients
Offers Telehealth
18 Years of Experience
Expertise in
27
conditions
Van Amburg And Busiek Mds LLC
232 S Woods Mill Rd, Suite 330e, 
Chesterfield, MO 
OverviewInsuranceLocationsClinical Research

Overview

Mark Fesler is a Hematologist Oncology specialist and a Transplant Surgeon in Chesterfield, Missouri. Dr. Fesler has been practicing medicine for over 18 years is highly rated in 27 conditions, according to our data. His top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML), Large-Cell Immunoblastic Lymphoma, Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Transplant. Dr. Fesler is currently accepting new patients.

His clinical research consists of co-authoring 22 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Transplant Surgery
Hematology
Licenses
Internal Medicine in CO
Hospital Affiliations
St Lukes Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Oscar
  •  Humana

Locations

VAN AMBURG AND BUSIEK MDS LLC
232 S Woods Mill Rd, Suite 330e, Chesterfield, MO 63017

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: January 23, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2024
Intervention Type: Drug, Other
Study Drugs: Brentuximab vedotin, Rituximab, Lenalidomide
Study Phase: Phase 3
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Enrollment Status: Active_not_recruiting
Publish Date: October 26, 2024
Intervention Type: Biological, Procedure
Study Drug: Rituximab
Study Phase: Phase 3
A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)
A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)
Enrollment Status: Terminated
Publish Date: October 13, 2023
Intervention Type: Drug
Study Drug: Brentuximab
Study Phase: Phase 2
A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma
A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma
Enrollment Status: Terminated
Publish Date: October 16, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

22 Total Publications

Killing Two Birds With One Stone: Successful Management With Rituximab in the Coexistence of Myasthenia Gravis and Marginal Zone Lymphoma.
Killing Two Birds With One Stone: Successful Management With Rituximab in the Coexistence of Myasthenia Gravis and Marginal Zone Lymphoma.
Journal: Cureus
Published: September 23, 2023
Similar Doctors
Expertise in
30
conditions
Dr. Brad S. Kahl
Oncology | Hematology Oncology
Expertise in
30
conditions
Dr. Brad S. Kahl
Oncology | Hematology Oncology

Washington University

4921 Parkview Pl, 
Saint Louis, MO 
 (13.1 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Brad Kahl is an Oncologist and a Hematologist Oncology provider in Saint Louis, Missouri. Dr. Kahl is highly rated in 30 conditions, according to our data. His top areas of expertise are Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, Follicular Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Kahl is currently accepting new patients.

John F. Dipersio
Expertise in
36
conditions
Dr. John F. Dipersio
Oncology | Hematology | Hematology Oncology
Expertise in
36
conditions
Dr. John F. Dipersio
Oncology | Hematology | Hematology Oncology

Washington University

4921 Parkview Pl, 
Saint Louis, MO 
 (13.1 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Dipersio is an Oncologist and a Hematologist in Saint Louis, Missouri. Dr. Dipersio is highly rated in 36 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Lymphoblastic Leukemia (ALL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Dipersio is currently accepting new patients.

Expertise in
17
conditions
Dr. Ramaswamy B. Govindan
Oncology | Hematology Oncology
Expertise in
17
conditions
Dr. Ramaswamy B. Govindan
Oncology | Hematology Oncology

Washington University

4921 Parkview Pl, 
Saint Louis, MO 
 (13.1 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ramaswamy Govindan is an Oncologist and a Hematologist Oncology provider in Saint Louis, Missouri. Dr. Govindan is highly rated in 17 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Squamous Cell Lung Carcinoma. Dr. Govindan is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile